Keyphrases
High Risk
100%
Respiratory Syncytial Virus
100%
Respiratory Syncytial Virus Bronchiolitis
100%
Rare Disorders
100%
Late Preterm
100%
Specific Prevention
100%
Respiratory Syncytial Virus Infection
57%
High-risk Population
28%
Life-threatening
14%
Prospective Cohort Study
14%
Caregivers
14%
Randomized Trial
14%
Low Incidence
14%
Illness
14%
Hospitalization
14%
Infections in children
14%
Epidemiological Study
14%
Medical Conditions
14%
Medical Illness
14%
Absolute Risk
14%
Specific Conditions
14%
Palivizumab
14%
Children with Congenital Heart Disease
14%
Lower Respiratory Tract Infection
14%
Chronic Lung Disease
14%
Preterm Infants
14%
Bronchiolitis
14%
F Protein
14%
Anti-respiratory Syncytial Virus
14%
Pharmacoeconomic Analysis
14%
Humanized Antibody
14%
Etiological Agents
14%
Traditional Wells
14%
Medicine and Dentistry
Human Respiratory Syncytial Virus
100%
Bronchiolitis
100%
Orphan Disorder
100%
Respiratory Syncytial Virus Infection
44%
Disease
22%
High Risk Population
22%
Infection
11%
Prospective Cohort Study
11%
Persistent Truncus Arteriosus
11%
Palivizumab
11%
Chronic Lung Disease
11%
Lower Respiratory Tract Infection
11%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Human Respiratory Syncytial Virus
100%
Bronchiolitis
100%
Respiratory Syncytial Virus Infection
44%
Infection
11%
Prospective Cohort Study
11%
Palivizumab
11%
Congenital Heart Disease
11%
Lower Respiratory Tract Infection
11%
Chronic Lung Disease
11%
Pharmacoeconomics
11%